U.S. Markets closed

Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data

Zacks Equity Research
1 / 2

Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data

The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).

Cardiovascular Systems, Inc. CSII recently released two-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago.

Notably, LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,204 patients across 51 sites in the United States, including 501 patients with claudication, 603 affected with critical limb ischemia (CLI) and 100 with the most severe form of CLI.

The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. Per the medical device manufacturer, LIBERTY 360° as an “all comers” study included all FDA-approved endovascular devices to treat PAD.

Cardiovascular Systems, Inc. Price

Cardiovascular Systems, Inc. Price | Cardiovascular Systems, Inc. Quote

The data from this study demonstrated a continued high freedom from major amputation in all Rutherford Classifications (RC) at the end of two-year observation period. Particularly, LIBERTY 360° showed that PVI can help prevent amputation even for RC6 patients with PAD, thus demonstrating a 79.8% freedom from major amputation following PVI. This piece of solid information is validated by the company itself.

Per the company’s press release, around 18 million Americans suffer the PAD, syndrome, caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture this niche market.

We also note in this regard that in February, the company announced the commercial launch of Diamondback 360 Coronary OAS Micro Crown in Japan.

Some noteworthy stocks in the broader industry are Haemonetics Corporation HAE, Stryker Corporation SYK and Lantheus Holdings, Inc. LNTH.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research